Online inquiry

IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12820MR)

This product GTTS-WQ12820MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MASP2 gene. The antibody can be applied in Atypical hemolytic uremic syndrome (aHUS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_006610.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10747
UniProt ID O00187
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12820MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2173MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ10413MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY2439821
GTTS-WQ14013MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ3467MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BA1126
GTTS-WQ1678MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACZ885
GTTS-WQ3377MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AT-005
GTTS-WQ2131MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALD-403
GTTS-WQ4416MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-663513
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW